In this article, we break down the Top 5 Best Biotech Stocks Wall Street Is Buying Aggressively Now. For investors looking for the complete list, you can explore our full report on the Top 10 Best Biotech Stocks Wall Street Is Buying Aggressively Now.
5. Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR)
Arrowhead Pharmaceuticals Inc. is building momentum around its obesity and metabolic disease pipeline, even as early data created mixed reactions. On March 26, TD Cowen reiterated its Buy rating following updates on the ARO-INHBE program.
Recent data released by Wave Life Sciences showed that monotherapy WVE-007, despite higher dosing, delivered weight and fat reduction below investor expectations. However, Arrowhead emphasized that ongoing research is refining the understanding of optimal inhibition targets, specifically INHBE and ALK7.
The company expanded its INHBE studies after observing promising signals in patients with Type 2 diabetes and in combination with tirzepatide. These findings suggest the therapy may be better suited for combination or maintenance settings rather than standalone use.
TD Cowen expects additional data later in the year, including closely watched sHTG results in the third quarter. Arrowhead’s broader pipeline includes RNAi-based therapies targeting multiple chronic and rare diseases, keeping it positioned as a long-term platform play rather than a single-asset bet.
Click next to see the following stock...
